| Identification | Back Directory | [Name]
2H-Furo[2,3-c]oxacyclotetradecin-3-carboximidamide, 15-ethyltetradecahydro-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-N'-[(1S)-1-[5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl]ethoxy]-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, [C(Z),3R,3aS,4R,6R,8R,9R,10R,12R,15R,15aS]- | [CAS]
1691240-78-4 | [Synonyms]
Nafithromycin
2H-Furo[2,3-c]oxacyclotetradecin-3-carboximidamide, 15-ethyltetradecahydro-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-N'-[(1S)-1-[5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl]ethoxy]-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, [C(Z),3R,3aS,4R,6R,8R,9R,10R,12R,15R,15aS]- | [Molecular Formula]
C42H62N6O11S | [MOL File]
1691240-78-4.mol | [Molecular Weight]
859.05 |
| Hazard Information | Back Directory | [Uses]
Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC90 of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter[1]. | [References]
[1] Kohlhoff, et al. "In vitro activity of nafithromycin (WCK 4873) against Chlamydia pneumoniae." Antimicrobial Agents and Chemotherapy 65.9 (2021): 10-1128. DOI:10.1128/AAC.00585-21 |
|
|